{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:52:37Z","timestamp":1791579157861,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007877","name":"Fujita Health University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25ym0126817"],"award-info":[{"award-number":["25ym0126817"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bbamcr.2026.120224","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:20:29Z","timestamp":1790137229000},"page":"120224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2\/NRF1 axis"],"prefix":"10.1016","volume":"1874","author":[{"given":"Atsumi","family":"Ota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sota","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Saka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riri","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayuki","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Fukuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbamcr.2026.120224_bb0005","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0010","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1158\/0008-5472.CAN-05-0201","article-title":"Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue","volume":"65","author":"Chen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0015","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0020","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/13543776.2023.2272648","article-title":"Proteasome inhibitors as anticancer agents","volume":"33","author":"Gazzaroli","year":"2023","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0025","doi-asserted-by":"crossref","first-page":"1351565","DOI":"10.3389\/fphar.2024.1351565","article-title":"Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells","volume":"15","author":"Pelon","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27072201","article-title":"Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance","volume":"27","author":"Leonardo-Sousa","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0035","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s11864-024-01273-6","article-title":"Acquired Bortezomib Resistance in Multiple Myeloma: From Mechanisms to Strategy","volume":"25","author":"Li","year":"2024","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25168949","article-title":"Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction","volume":"25","author":"Tyrna","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nsmb.1386","article-title":"Crystal structure of a chaperone complex that contributes to the assembly of yeast 20S proteasomes","volume":"15","author":"Yashiroda","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0050","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The Logic of the 26S Proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","article-title":"Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells","volume":"38","author":"Radhakrishnan","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0060","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cub.2014.06.004","article-title":"Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97","volume":"24","author":"Sha","year":"2014","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.molcel.2010.09.012","article-title":"Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop","volume":"40","author":"Steffen","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0070","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01856","article-title":"p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition","volume":"3","author":"Radhakrishnan","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0075","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18357","article-title":"The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction","volume":"5","author":"Koizumi","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2023.194937","article-title":"UBE4A catalyzes NRF1 ubiquitination and facilitates DDI2-mediated NRF1 cleavage","volume":"1866","author":"Hu","year":"2023","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0085","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1021\/acscentsci.7b00224","article-title":"Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity","volume":"3","author":"Tomlin","year":"2017","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2020003820","article-title":"Multiple myeloma cells depend on the DDI2\/NRF1-mediated proteasome stress response for survival","volume":"6","author":"Chen","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41419-022-04925-3","article-title":"The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma","volume":"13","author":"Op","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051065","article-title":"Nelfinavir Inhibits the TCF11\/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma","volume":"12","author":"Fassmannov\u00e1","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109775","article-title":"Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors","volume":"75","author":"Gu","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0110","doi-asserted-by":"crossref","first-page":"30443","DOI":"10.1038\/srep30443","article-title":"Human DNA-Damage-Inducible 2 Protein Is Structurally and Functionally Distinct from Its Yeast Ortholog","volume":"6","author":"Siva","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0115","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/2211-5463.12491","article-title":"Crystal structure of the retroviral protease-like domain of a protozoal DNA damage-inducible 1 protein","volume":"8","author":"Kumar","year":"2018","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0120","doi-asserted-by":"crossref","first-page":"33671","DOI":"10.1038\/srep33671","article-title":"Structural studies of the yeast DNA damage-inducible protein Ddi1 reveal domain architecture of this eukaryotic protein family","volume":"6","author":"Trempe","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/jb\/mvab025","article-title":"Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells","volume":"170","author":"Endo","year":"2021","journal-title":"J. Biochem."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0130","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1021\/acs.jmedchem.1c02113","article-title":"Discovery and Structure-Based Optimization of Novel Atg4B Inhibitors for the Treatment of Castration-Resistant Prostate Cancer","volume":"65","author":"Kudo","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0135","first-page":"215","article-title":"Evaluation of compound selectivity of aldo-keto reductases using differential scanning fluorimetry","volume":"161","author":"Kabir","year":"2017","journal-title":"J. Biochem."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0140","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","article-title":"Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer","volume":"63","author":"Endo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2023.109824","article-title":"Activation of the TGF-\u03b21\/EMT signaling pathway by claudin-1 overexpression reduces doxorubicin sensitivity in small cell lung cancer SBC-3\u00a0cells","volume":"751","author":"Nagaoka","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0150","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1160\/TH04-11-0712","article-title":"Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1","volume":"93","author":"Setyono-Han","year":"2005","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0155","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/bjc.2013.62","article-title":"Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer","volume":"108","author":"Heinemann","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0160","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1021\/jm061066t","article-title":"Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines","volume":"50","author":"Fish","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0165","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2050-7771-1-13","article-title":"The resistance mechanisms of proteasome inhibitor bortezomib","volume":"1","author":"Lu","year":"2013","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drup.2014.12.001","article-title":"Molecular basis of resistance to proteasome inhibitors in hematological malignancies","volume":"18","author":"Niewerth","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0180","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.leukres.2011.09.011","article-title":"Bortezomib resistance in a myeloma cell line is associated to PSMbeta5 overexpression and polyploidy","volume":"36","author":"Balsas","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-22-1161","article-title":"Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma","volume":"29","author":"Haertle","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0190","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/bloodadvances.2022007875","article-title":"SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma","volume":"7","author":"Heynen","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0195","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00277-024-06163-3","article-title":"Metabolic reprogramming induced by PSMA4 overexpression facilitates bortezomib resistance in multiple myeloma","volume":"104","author":"Yu","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0200","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41467-023-37013-x","article-title":"Deacetylation induced nuclear condensation of HP1gamma promotes multiple myeloma drug resistance","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0205","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1182\/bloodadvances.2021004315","article-title":"DKK1 activates noncanonical NF-kappaB signaling via IL-6-induced CKAP4 receptor in multiple myeloma","volume":"5","author":"Li","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0210","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/s41388-019-1037-6","article-title":"Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma","volume":"39","author":"Xie","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0215","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/15384101.2015.1136038","article-title":"TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-\u03baB inhibition","volume":"15","author":"Raninga","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0220","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107801","article-title":"Discovery of novel 20S proteasome subunit beta5 PROTAC degraders as potential therapeutics for pharyngeal carcinoma and Bortezomib-resistant multiple myeloma","volume":"153","author":"Wang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0230","article-title":"Unification of Opposites between Two Antioxidant Transcription Factors Nrf1 and Nrf2 in Mediating Distinct Cellular Responses to the Endoplasmic Reticulum Stressor Tunicamycin","volume":"9","author":"Zhu","year":"2019","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0235","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1136\/gutjnl-2020-321548","article-title":"ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis","volume":"70","author":"Hao","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12185-023-03705-9","article-title":"Acute accumulation of PIM2 and NRF2 and recovery of beta5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors","volume":"119","author":"Sogabe","year":"2024","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bbamcr.2026.120224_bb0245","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91678","article-title":"Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2","volume":"12","author":"Ibtisam","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.bbamcr.2026.120224_bb0250","doi-asserted-by":"crossref","first-page":"14405","DOI":"10.1038\/s41598-023-41492-9","article-title":"The transcription factor NRF1 (NFE2L1) activates aggrephagy by inducing p62 and GABARAPL1 after proteasome inhibition to maintain proteostasis","volume":"13","author":"Hatanaka","year":"2023","journal-title":"Sci. Rep."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926001230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926001230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:28:18Z","timestamp":1791577698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488926001230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S0167488926001230"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120224","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2\/NRF1 axis","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120224"}}